Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Unilife Signs Drug Delivery Contract | Contract Pharma

What are you searching for?

Sign in
Breaking News

Unilife Signs Drug Delivery Contract

To supply customized EZMix dual-chamber syringe in 15-year deal

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Unilife Corp. has signed a customization and commercial supply agreement with a U.S. pharmaceutical company for the EZMix dual-chamber syringe. Unilife will supply a customized device from its EZMix platform of delivery systems for use with a lyophilized drug that requires mixing at the time of injection. The drug, which is a proprietary version of an approved therapy, is entering late-stage development.
 
Unilife anticipates as much as $110 million in revenue during the 15-year agreement, based on a customization and production scale-up program, commercial device sales and a royalty on sales. Unilife will receive approximately $3 million during a 12- to 24-month period for the supply of prefilled EZMix devices for clinical trials and compatibility testing, and an additional $3 million to fund the production scale-up to manufacture commercial volumes.
 
Alan Shortall, chief executive officer of Unilife, said, “As the world’s only dual-chamber syringe with intuitive, ventless, orientation-free mixing and automatic needle retraction, EZMix is a game-changing technology for the delivery of liquid-liquid or liquid-dry drug combination therapies. Compared to conventional technologies which can take between five and a dozen complex steps to mix together the drug and diluent combination, EZMix can essentially achieve the same outcome with one easy, single-handed action. That makes EZMix an enabling technology for combination therapies targeted for use by healthcare workers or self-injecting patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics